General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection and Electrical Impedance Spectrometers, To Be Renamed Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer
FDA reclassifies optical diagnostic devices for melanoma detection and electrical impedance spectrometers from Class III to Class II, renaming them as 'Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer.' This reclassification imposes new special controls, including clinical performance testing, software validation, and human factors testing, and requires premarket notification (510(k)) clearance.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on July 29, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Manufacturers of optical diagnostic devices for melanoma detection and electrical impedance spectrometers, including health tech startups and medical device companies developing AI/ML-based skin lesion analysis software. should confirm how it applies to their specific situation before acting. There is a time constraint attached: The reclassification is effective 30 days after publication in the Federal Register (publication date March 25, 2026). Devices already on the market under PMA may have a grace period; consult FDA guidance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Devices are reclassified from Class III (requiring PMA) to Class II (requiring 510(k) clearance) with new special controls: clinical performance testing, software verification/validation, human factors testing, and labeling requirements. The device name is changed to 'Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians Trained in the Diagnosis and Management of Skin Cancer.'
Who it affects
Manufacturers of optical diagnostic devices for melanoma detection and electrical impedance spectrometers, including health tech startups and medical device companies developing AI/ML-based skin lesion analysis software.
What you must do
Manufacturers must submit a 510(k) premarket notification to FDA demonstrating compliance with the new special controls before marketing. Existing devices with PMA may need to transition; confirm with FDA.
Deadline
The reclassification is effective 30 days after publication in the Federal Register (publication date March 25, 2026). Devices already on the market under PMA may have a grace period; consult FDA guidance.
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
- HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information
- Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions To Unleash Prosperity
- Nondiscrimination in Health Programs and Activities
- Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing